Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Abstract

Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. Methods We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15. Results A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P=0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, −5.0 percentage points; 95% CI, −9.8 to −0.3; P=0.03), as were new infections (5.9% vs. 11.2%; difference, −5.3 percentage points; 95% CI, −8.7 to −1.9; P=0.003). Conclusions Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579 .)

The Rheumatology Drugs for COVID-19 Management: Which and When?

“…Among the various treatments proposed, there is baricitinib. Certainly, the first results of these clinical trials will be able to clarify what is the role of baricitinib in the treatment of COVID-19 [107].…”

Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19

“…Treatment directly targeting viral replication can target viral proteins (e.g. remdesivir 2 ), or host proteins upon which the virus depends 3 . Host-targeted therapies may have an important role in infectious diseases in general, and the only treatment so far found to reduce mortality in COVID-19—dexamethasone 4 —is likely to act by targeting host immune-mediated organ damage 5 .…”

“…Other host-directed treatments (e.g. anakinra, tocilizumab, sarilumab, mavrilimumab), repurposed from other indications, are currently under investigation 2 , 6 – 10 .…”

Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?

“…Based on the emergency of COVID-19, there are no drug therapies developed exclusively for this infection. The antiviral remdesivir was approved for the treatment of COVID-19 in hospitalized adult and pediatric patients since it reduced patients’ recovery time (Beigel et al 2020 ). Additionally, dexamethasone use resulted in lower mortality among patients hospitalized with COVID-19, receiving either invasive mechanical ventilation or oxygen alone at randomization ( 2020 ).…”